Increase in serum leptin concentrations among women with endometriosis during danazol and leuprolide depot treatments

• Published in: American journal of obstetrics and gynecology 2000-07, Vol.183 (1), p.58-62
• Main Authors: MATALLIOTAKIS, I. M, KOUMANTAKI, Y. G, NEONAKI, M. A, GOUMENOU, A. G, KOUMANTAKIS, G. E, KYRIAKOU, D. S, KOUMANTAKIS, E. E
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Biological and medical sciences; Danazol - adverse effects; Danazol - therapeutic use; Endometriosis - blood; Endometriosis - complications; Endometriosis - drug therapy; Estrogen Antagonists - adverse effects; Estrogen Antagonists - therapeutic use; Female; Hormones. Endocrine system; Humans; Infertility, Female - blood; Infertility, Female - etiology; Leptin - metabolism; Leuprolide - adverse effects; Leuprolide - therapeutic use; Medical sciences; Pharmacology. Drug treatments
• ISSN: 0002-9378; 1097-6868
• DOI: 10.1016/S0002-9378(00)78147-6

This study was undertaken to evaluate serum leptin concentrations in women with endometriosis during treatment with danazol and with leuprolide depot. Twenty patients aged 18 to 42 years with regular menses and documented pelvic endometriosis were recruited from a university hospital setting. Treatment was 200 mg danazol 3 times daily for 6 months or 3.75 mg leuprolide depot every 28 days for 6 months. Serum leptin concentrations were measured before, during, and after treatment. A single blood sample was taken from each of 10 control women without endometriosis for comparison. Serum leptin level was measured with a radioimmunoassay kit with human leptin, and analysis of variance and paired t tests were used for statistical analysis. Serum leptin levels were almost the same among women with endometriosis as in the control group. Leptin levels were higher among women with endometriosis during treatment with danazol and leuprolide(P